Regulation - Asia-Pacific, Diabetes


Current filters:


Popular Filters

Takeda files for diabetes drug trelagliptin succinate approval in Japan

Takeda files for diabetes drug trelagliptin succinate approval in Japan


Takeda Pharmaceutical, Japan’s largest drugmaker, has submitted a New Drug Application to the Japanese…

Asia-PacificBlopressCardio-vascularDiabetesJapanPharmaceuticalRegulationResearchTakeda Pharmaceuticalstrelagliptin

Astellas gains Japanese clearance for diabetes drug Suglat

Astellas gains Japanese clearance for diabetes drug Suglat


Japanese drug major Astellas Pharma has obtained the marketing approval of selective SGLT2 inhibitor…

Asia-PacificAstellas PharmaDiabetesipragliflozinKotobuki PharmaceuticalMerck & CoPharmaceuticalRegulationSuglat

Indication changes for Glufast approved in Japan


Japanese drugmakers Kissei Pharmaceutical (TYO: 4547) and Takeda Pharmaceutical (TYO: 4502) have received…

Asia-PacificDiabetesGlufastKissei PharmaceuticalPharmaceuticalRegulationTakeda Pharmaceuticals

Takeda gains Chinese approval for diabetes drug


Japan's largest drugmaker, Takeda Pharmaceutical (TYO: 4502), says that the China Food and Drug Administration…

Asia-PacificDiabetesNesinaPharmaceuticalRegulationSanofiTakeda Pharmaceuticals

Zydus' diabetes drug Lipaglyn becomes India's first NCE to reach the market


Indian drugmaker Zydus Cadila today (June 5) made a breakthrough in its research efforts with Lipaglyn…

Asia-PacificDiabetesLipaglynPharmaceuticalRegulationZydus Cadila

Astellas files for Japanese approval of ipragliflozin for types 2 diabetes


Japanese drug major Astellas Pharma (TYO: 4503) has submitted a market authorization application for…

Asia-PacificAstellas PharmaDiabetesipragliflozinPharmaceuticalRegulation

Japanese approvals for Novo's Ryzodeg, UCB/Otsuka's Neupro and B-MS/Pfizer's Eliquis


Danish insulin giant Novo Nordisk (NOVN: NV) revealed on December 15 that the Japanese Ministry of Health,…

Asia-PacificBristol-Myers SquibbCardio-vascularDiabetesEliquisNeuproNeurologicalNovo NordiskOtsukaPfizerPharmaceuticalRegulationRyzodegUCB

Novo Nordisk's Ryzodeg passes regulatory hurdle in Japan; diabetes burden review


Global insulin market leader Novo Nordisk (NOV: N) of Denmark revealed this morning that its Ryzodeg…

Asia-PacificDegludecDiabetesGlobalHealthcareNovo NordiskPharmaceuticalPricingRegulationRyzodegTresiba

EMA panel backing for Novo Nordisk's Tresiba and Ryzodeg: Japanese review


The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on Friday announced…

Asia-PacificDegludecDiabetesEuropeNovo NordiskPharmaceuticalRegulationRyzodegTresiba

Novo Nordisk insulin degludec passes first regulatory hurdle in Japan


Danish insulin giant Novo Nordisk (NOV: N) revealed on Friday that its ultra-long-acting insulin degludec…

Asia-PacificDegludecDiabetesNovo NordiskPharmaceuticalRegulation

Sanofi files for Japanese approval of diabetes drug Lyxumia


French drug major Sanofi (Euronext: SAN), has submitted a marketing authorization application for lixisenatide…

Asia-PacificDiabeteslixisenatideLyxumiaPharmaceuticalRegulationSanofiZealand Pharma

New Zealand considers listing of NovoMix 30 and NovoSeven RT and amendment for Glucagen Hypokit


The Pharmaceutical Management Agency of New Zealand, PHARMAC, is seeking feedback on a proposal to fund…

Asia-PacificDiabetesGlucaGenNovo NordiskNovoMixNovoSevenPharmaceuticalPricingRegulation

Drug approval and launch for Novartis in China, where Quintiles expands


Swiss drug major Novartis (NOVN: VX) says it has received regulatory approval in China from the State…

Asia-PacificDiabetesGalvusLucentisMarkets & MarketingNovartisOphthalmicsPharmaceuticalQuintilesRegulationResearch

Lundbeck submits Selincro in EU; Novo Nordisk files Degludec in Japan


Danish CNS drug specialist Lundbeck (LUND: DC) revealed yesterday that it has submitted a marketing authorization…

Asia-PacificBiotie TherapiesDegludecDiabetesEuropeLundbeckNeurologicalNovo NordiskPharmaceuticalRegulationSelincro

AstraZeneca to investment $200 million in Chinese manufacturing plant; Novo Nordisk debuts Victoza


Anglo-Swedish drug major AstraZeneca ILSE: AZN) said this morning that it is investing $200 million in…

Asia-PacificAstraZenecaDiabetesFinancialMarkets & MarketingNovo NordiskPharmaceuticalRegulationVictoza

Back to top